Farglitazar
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
Product Specifications
CAS Number
[196808-45-4]
Product Name Alternative
GI262570; GI262570X
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/farglitazar.html
Concentration
10mM
Purity
99.50
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC=C1)C2=C(C=CC=C2)N[C@H](C(O)=O)CC3=CC=C(C=C3)OCCC4=C(C)OC(C5=CC=CC=C5)=N4
Molecular Formula
C34H30N2O5
Molecular Weight
546.61
References & Citations
[1]Chen L, Yang B, McNulty JA, et al. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther. 2005;312 (2) :718-725.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-5317R-BF555 100 µL
Phospho-EGFR (Tyr1197) Polyclonal Antibody, AbBy Fluor™ 555 Conjugated
Sign In for Pricing
View Details 
C7904-43F-ML550 100 µL
COT, phosphorylated (Thr290) (Cancer Osaka Thyroid Oncogene, c-COT, EST, ESTF, Mitogen-activated Protein Kinase Kinase Kinase 8, MAP3K8, MEKK8, Proto-oncogene c-Cot, Serine/threonine-protein Kinase Cot, Tumor Progression Locus 2, TPL2, TPL-2) (MaxLight 550) discontinued
Sign In for Pricing
View Details 